I can almost guarantee their talk about PNV's competitor does not come from a place of medical knowledge.
I think it's likely that a major contribution of the shorts comes from "professionals" looking at ARX and AVH and thinking the space is so competitive, not realising one isn't a competitor and one is simply another biologic (and the issues that come with that).
This is all purely in my opinion and I could very well be wrong. Maybe I'm just hoping we are outsmarting the shorters. We did last year after all haha.
PNV - Banter and General Comments, page-5593
-
- There are more pages in this discussion • 7,092 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.35 |
Change
-0.080(3.29%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.43 | $2.35 | $1.817M | 764.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4119 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.37 | 8809 | 3 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |